Listed by the USPTO as BENAVIDES, JENNIFER ANN
Tech Center 1700 • Art Units: 1641 1649 1654 1675 1797
This examiner grants 51% of resolved cases
BENAVIDES, Jennifer Ann has resolved 122 cases in Tech Center 1700 and records a 50.8% allowance rate. The 47.3% interview lift is a strong signal that direct examiner engagement may substantially improve outcomes. The median time to allowance is 1184 days, so applicants should prepare interview positions early and maintain a strategy for extended prosecution.
Novartis AG, Regeneron Pharmaceuticals Inc., and Arizona Board of Regents on Behalf of the University of Arizona are the leading companies. WOLF GREENFIELD & SACKS, P.C., FOLEY & LARDNER LLP, and K&L Gates - Novartis are the leading firms. In art unit 1641, interviews should be paired with carefully supported claim amendments.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18271584 | ANTICANCER COMPOUNDS AND USES THEREOF | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18672871 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | Non-Final OA | Novartis AG |
| 18454457 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | Non-Final OA | Novartis AG |
| 19358181 | METHODS OF TREATING TUMORS | Final Rejection | Halozyme, Inc. |
| 18026746 | METHODS OF TREATING AN INDIVIDUAL THAT HAS FAILED AN ANTI-PD-1/ANTI-PD-L1 THERAPY | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 17779499 | COMBINATION THERAPY FOR HEAD AND NECK CANCER | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18383398 | METHODS OF IMPROVING NEURODEGENERATIVE DISORDERS BY TARGETED DELIVERY OF THERAPEUTIC AGENTS | Non-Final OA | West Virginia University Board of Governors on behalf of West Virginia University |
| 18509136 | ANTI-FGFR3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS AND METHODS OF USE THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17112198 | METHODS FOR TREATING COPD BY ADMINISTERING AN IL-33 ANTAGONIST | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17622634 | MODULATION OF DENDRITIC CELL FUNCTION BY THE PHOSPHOLIPID MESSENGER LPA | Final Rejection | Cornell University |
| 17817178 | THERAPEUTIC FRACTIONS AND PROTEINS FROM ASTHMA-PROTECTIVE FARM DUST | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 17413468 | BARN DUST EXTRACT FOR THE PREVENTION AND TREATMENT OF DISEASES | Non-Final OA | The Arizona Board of Regents on Behalf of the University of Arizona |
| 17776556 | Combination Therapy Based on PD-1 Signaling Inhibitors | Non-Final OA | Kyoto University |
| 18278394 | INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF | Final Rejection | Children's Medical Center Corporation |
| 16624422 | CAPTURE OF CIRCULATING TUMOR CELLS USING CARBON NANOTUBE SPONGES | Final Rejection | UNIVERSITY OF DELAWARE |
| 18051993 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | Final Rejection | University of Leicester |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy50.8% of resolved applications examined by Jennifer Ann Benavides were allowed (122 resolved cases), compared with 45.2% across Art Unit 1641 over the last five years.
This examiner's interview lift is +47.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Jennifer Ann Benavides took 1,184 days on average from filing to allowance.
Jennifer Ann Benavides examines applications in Art Unit 1641 in Tech Center 1700 (Chemistry & Materials).
